9 Followers on Owler

ITI

develops lysosomal-associated membrane protein vaccines for the treatment of cancer, allergy and infectious diseases... Read more
OverviewCompetitorsFundingNews & Insights

ITI

develops lysosomal-associated membrane protein vaccines for the treatment of cancer, allergy and infectious diseases... Read more
ITI CEO: Dong-Gun Kim

CEO

Dong-Gun Kim

CEO Approval Rating

82/100

2005

PrivateAcquired by HLB Ltd

Pharmaceuticals & Biotechnology
PharmaceuticalsBiotechnology
28342836 NAICS listing

Est. Annual Revenue
$5.0-25M
Agree?
Est. Employees
25-100
Agree?
Funding
$106.2M

News

Funding
Jun 02, 2025
SEC
ITI received $6.5M in Equity Funding

ITI Competitors

1Agios
2Aimmune
3DBV Technologies
4Novo Nordisk
5AstraZeneca
6ESSA
7Array BioPharma
8Pfizer
9Lilly
10Novartis
Unlock 25 + competitors

Trending Companies